Mesothelioma was long considered a cancer that stayed close to home, creeping along the pleural lining and destroying nearby structures rather than spreading to distant organs. That picture has changed substantially. Modern imaging and longer patient survival have revealed that roughly two-thirds of people with malignant pleural mesothelioma develop distant metastatic disease during the course of their illness, with the contralateral lung, lymph nodes, bone, and peritoneum among the most commonly affected sites. Understanding where and how mesothelioma spreads matters for staging, treatment planning, and recognizing symptoms before they become emergencies.
Where Mesothelioma Spreads Most Often
The most consistent finding across studies is that when pleural mesothelioma does metastasize, it tends to favor a handful of destinations. A population-based study using a machine learning model found the contralateral lung was the most common distant site (about 19% of metastatic cases), followed by distant lymph nodes (roughly 18%), bone (about 14%), and liver (around 7%), with brain metastases being uncommon at under 2%.1PubMed Central. Distant Metastatic Pattern and Its Prognostic Significance in Malignant Pleural Mesothelioma: A Population‐Based Study Based on a Machine Learning Model A radiological study of patients being considered for aggressive treatment reported even higher rates, with contralateral lung involvement in about 35%, peritoneal spread in 22%, bone in 19%, and visceral organ metastases in 14%.2PubMed Central. Radiological evaluation of malignant pleural mesothelioma – defining distant metastatic disease
Bone metastases deserve particular attention because they are often lytic, meaning they destroy bone tissue rather than building it up. In one modern-era case series, bone involvement was found in about 20% of patients, with the majority of lesions being lytic in nature. The same study noted that peritoneal and omental disease appeared in roughly a quarter of patients, and about 11% had lung metastases presenting as a diffuse, miliary-type pattern, which means tiny tumor deposits scattered widely through the lung tissue rather than discrete lumps.3Journal of Clinical Oncology. Patterns of metastases in malignant pleural mesothelioma in the modern era: Redefining the spread of an old disease Brain metastases remain rare but are disproportionately significant because they often force a complete change in treatment strategy. In a cohort screened for multimodal therapy, cerebral imaging at the time of diagnosis identified brain metastases in about 3.6% of patients, and all of them were shifted from aggressive treatment to chemotherapy alone.4PubMed Central. The Incidence of Distant Metastases in Patients with Pleural Mesothelioma Screened for a Multimodal Approach: How Much Staging Do We Really Need?
How the Number of Metastatic Sites Affects Survival
Not all metastatic disease carries the same prognosis. A patient with a single distant metastasis fares meaningfully better than one with multiple sites involved. The population-based study noted that patients with a single distant lesion had a median overall survival of about 9 months, compared to 6 months for those with multiple metastatic deposits. Among patients with just one metastatic site, those with isolated distant lymph node involvement had the best outlook.5PubMed Central. Distant Metastatic Pattern and Its Prognostic Significance in Malignant Pleural Mesothelioma: A Population‐Based Study Based on a Machine Learning Model This distinction between single-site and multi-site disease has practical consequences: patients with limited spread may still be candidates for certain localized treatments, while widespread dissemination typically narrows options to systemic therapy and supportive care.
How Mesothelioma Reaches Distant Sites
The routes mesothelioma takes to spread are somewhat unusual compared to most solid cancers. Because mesothelioma arises from the pleural lining rather than from an organ, its initial growth pattern involves creeping along that membrane, encasing the lung, and invading adjacent structures like the chest wall, diaphragm, and pericardium. Distant spread appears to involve several pathways.
Lymphatic drainage plays a key role, but in a pattern that surprised researchers. A surgical series examining lymph node involvement found that hilar nodes, which sit near where the bronchial tubes enter the lung, were only positive in patients whose tumors had already invaded the lung tissue itself. None of the patients without lung invasion had positive hilar nodes. This led to the observation that mediastinal lymph nodes should be considered the primary station in mesothelioma, and that hilar node involvement requires lung invasion first rather than direct spread from the pleura.6PubMed. Prevalence and pattern of lymph node metastasis in malignant pleural mesothelioma In other words, mesothelioma has to break into the lung before it can access the hilar lymph node highway.
At the molecular level, a process called epithelial-to-mesenchymal transition plays a central role. This is a shift where tumor cells lose the characteristics that keep them stuck in place and acquire traits that allow them to move and invade. In mesothelioma, asbestos fibers themselves can trigger this shift by increasing oxidative stress and certain growth signals in the mesothelium. Once this transition is underway, the cancer cells gain invasive properties marked by increased levels of movement-related proteins.7PubMed Central. The Epithelial-to-Mesenchymal Transition (EMT) in the Development and Metastasis of Malignant Pleural Mesothelioma Lab studies have shown that even epithelioid mesothelioma cells, the subtype traditionally considered the least aggressive, can develop spindle-shaped, mesenchymal features under certain conditions, with a key regulatory protein called Zeb1 appearing at the invasion front of these tumors.8PubMed Central. Epithelial-Mesenchymal Plasticity in the D-Meso-Sonobe Mesothelioma Cell Line: A Putative Model of Epithelial-Mesenchymal Transition in Mesothelioma
The tissue-remodeling machinery that enables invasion also differs between mesothelioma and normal mesothelium. Tumor samples show significantly higher levels of proteins like MMP14 and integrin alpha-3, which are enzymes and adhesion molecules that help cancer cells chew through surrounding tissue and latch onto new sites.9PubMed. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia Additionally, new blood vessel formation driven by vascular endothelial growth factor provides both a nutrient supply and a route for tumor cells to enter the bloodstream. VEGF and a related molecule called VEGF-C are closely associated with blood vessel and lymphatic vessel density in mesothelioma tumors, suggesting both routes serve as highways for spread.10PubMed Central. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
Does Histological Subtype Predict Metastasis?
Mesothelioma comes in three main histological flavors: epithelioid, sarcomatoid, and biphasic (a mix of the two). A common assumption is that sarcomatoid tumors, which are more aggressive and have a worse prognosis, would metastasize more often. The reality is more nuanced. One study specifically looking at extrathoracic metastases found that they were equally common in nonepithelioid and epithelioid mesothelioma, with 44% of patients in each group developing distant spread.11JTO Clinical and Research Reports. Extrathoracic Metastases in Pleural Mesothelioma This is a somewhat surprising finding, because sarcomatoid histology is generally considered much more biologically aggressive. It suggests that the tendency to metastasize is not simply a function of how “bad” the subtype looks under a microscope.
That said, subtype does seem to influence where metastases appear. In one screening cohort, all four patients with cerebral metastases at diagnosis had the biphasic subtype, while the majority of patients who developed abdominal and bone metastases over time had the epithelioid subtype.12PubMed Central. The Incidence of Distant Metastases in Patients with Pleural Mesothelioma Screened for a Multimodal Approach: How Much Staging Do We Really Need? The subtypes also differ at the molecular level in ways that likely affect their behavior. Sarcomatoid tumors tend to express high levels of stromal proteins like periostin, while epithelioid tumors express higher levels of growth factor receptors and cell cycle regulators.13European Journal of Cardio-Thoracic Surgery. Prognostic significance of epithelial–mesenchymal transition in malignant pleural mesothelioma
Genetic Factors That Accelerate Spread
Among the genetic alterations linked to mesothelioma, loss of the BAP1 tumor suppressor stands out. In animal models, mice carrying a germline mutation in one copy of the BAP1 gene developed mesotheliomas after asbestos exposure that were consistently larger and more aggressive than those in normal mice. These tumors frequently invaded the pancreas, liver, and intestinal muscle, with occasional lung metastases, and showed higher rates of cell division.14Cancer Research. Germline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma In humans, BAP1 mutations are found in a significant minority of mesothelioma cases and are also associated with a familial cancer syndrome that predisposes people to mesothelioma, uveal melanoma, and certain other cancers. The connection between BAP1 loss and metastatic behavior helps explain why some patients develop rapidly spreading disease while others with similar asbestos exposure histories progress more slowly.
Procedure Tract Seeding
Mesothelioma has a distinctive tendency to seed itself along the tracks of needles and surgical instruments used during diagnosis. This phenomenon, sometimes called procedure-tract metastasis, occurs because the soft, sheet-like tumor can be dragged along by instruments as they are withdrawn through the chest wall. A study of 308 patients found malignant cell dissemination in resected surgical tracts in about 22% of cases. For patients with epithelioid mesothelioma, those who developed tract seeding had a median survival of roughly 20 months from diagnosis, compared to about 36 months for those without seeding.15PubMed Central. Malignant Local Seeding in Procedure Tracts of Pleural Mesothelioma: Incidence and Novel Risk Factors in 308 Patients
The risk is not equal across all procedures. The number of thoracoscopy ports used during biopsy increases the risk of tract dissemination, and pleurodesis, a procedure used to prevent fluid re-accumulation by gluing the pleural surfaces together, appears to be an independent risk factor. In one analysis, the rate of chest wall metastasis at biopsy sites was substantially higher in patients who underwent pleurodesis after biopsy compared to those who did not.16PubMed Central. Incidence and Risk Factors of Chest Wall Metastasis at Biopsy Sites in Patients with Malignant Pleural Mesothelioma This creates an uncomfortable tension: pleurodesis is one of the most effective ways to manage recurrent pleural effusions, yet it may also promote local spread along intervention sites.
Detecting Metastatic Disease
Standard CT scanning misses a meaningful fraction of distant spread. A comparison of PET/CT and conventional CT found that PET/CT detected intrathoracic lymph node involvement and extrathoracic metastases at roughly double the rate of CT alone (about 37% versus 18%), largely because PET imaging picks up metabolically active deposits that may not yet be large enough to see on anatomy-based scans.17QJM: An International Journal of Medicine. Use of PET/CT in Diagnosis and Staging of Malignant Pleural Mesothelioma For post-surgical surveillance, PET/CT also outperformed contrast-enhanced CT in diagnosing both locoregional recurrence and distant metastases, including peritoneal spread and deposits in bone, muscle, and liver.18PubMed Central. Clinical utility of FDG-PET/CT for post-surgery surveillance of malignant pleural mesothelioma – Comparison with contrast-enhanced CT
Because mesothelioma diagnosis still relies heavily on invasive tissue biopsy, there is strong interest in so-called liquid biopsies, which would detect circulating tumor markers in a blood sample. For asbestos-exposed populations who need long-term monitoring, a reliable blood test could identify disease earlier and flag metastatic spread without repeated imaging. However, circulating biomarkers for early diagnosis remain to be identified, and no liquid biopsy test has yet reached clinical routine for mesothelioma.19PubMed Central. Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives
Peritoneal Versus Pleural Mesothelioma
Mesothelioma can also arise in the abdomen, from the peritoneal lining. These two forms of the disease have historically been lumped together, but they behave differently when it comes to spread. A comparative study found that metastatic disease was more common in peritoneal mesothelioma than in pleural mesothelioma (34% versus 20%).20Lung Cancer. Different Diseases, Different Outcomes: A Comparative Study of Peritoneal and Pleural Subtypes Peritoneal mesothelioma tends to disseminate within the abdominal cavity, coating the intestines, liver surface, and omentum, whereas pleural mesothelioma more often sends deposits to the contralateral lung, bone, and mediastinal nodes. The treatment approaches also diverge: peritoneal mesothelioma may be treated with cytoreductive surgery combined with heated intraperitoneal chemotherapy, a strategy rarely applicable to the pleural form.
Treatment Options for Metastatic Disease
For unresectable or metastatic mesothelioma, immunotherapy has become the standard first-line treatment. The landmark CheckMate 743 trial compared a combination of nivolumab and ipilimumab, two immune checkpoint inhibitors, against standard chemotherapy. At a median follow-up of roughly 30 months, the immunotherapy combination extended median overall survival to about 18 months versus 14 months with chemotherapy, and two-year survival rates were 41% versus 27%.21PubMed. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial Five-year follow-up data confirmed that the benefit held up over time, with 14% of immunotherapy patients alive at five years compared to 6% of those who received chemotherapy. The survival benefit persisted regardless of tumor histology.22PubMed Central. Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
For patients whose disease progresses at a limited number of sites, stereotactic body radiation can provide durable local control. In a series where the majority of patients had five or fewer progressive sites, focused radiation achieved a one-year local control rate of about 93%, with no severe toxicities. The most common treated locations were the pleura itself, followed by the spine and other bones.23PubMed Central. Clinical outcomes of stereotactic body radiation therapy for malignant pleural mesothelioma A broader systematic review of locoregional therapies in advanced mesothelioma reported one-year local control rates ranging from about 74% to 100% across radiotherapy series, with median overall survival ranging from roughly 27 to 38 months.24Lung Cancer. Locoregional therapies in advanced and recurrent pleural mesothelioma: A systematic review
CAR T-Cell Therapy and the Mesothelin Target
One of the more experimental frontiers involves engineering a patient’s own immune cells to attack mesothelioma. Mesothelin, a protein found at high levels on mesothelioma cells but at low levels on healthy tissue, is an appealing target for chimeric antigen receptor T-cell therapy. Clinical trials using anti-mesothelin CAR T cells have shown that the approach is relatively safe, but so far the results have been modest because the tumor’s microenvironment suppresses the engineered cells, reducing their ability to infiltrate, persist, and kill.25PubMed Central. Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
One strategy to overcome that suppression involves combining CAR T cells with checkpoint inhibitors. In a phase I trial, patients with mesothelioma who received mesothelin-targeted CAR T cells infused directly into the pleural space along with pembrolizumab, a PD-1 inhibitor, achieved a median overall survival of nearly 24 months from the time of CAR T-cell infusion, with about 83% alive at one year.26Cancer Discovery. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab These are early-phase numbers with a small patient group, so they should be interpreted cautiously. But the combination of local delivery and immune checkpoint blockade represents one of the more promising directions in a cancer that has historically resisted treatment.
Managing Pleural Effusions in Advanced Disease
For many patients with mesothelioma, the most immediate quality-of-life issue is not a distant metastasis but the relentless accumulation of fluid in the pleural space. Most patients experience this at some point, and it causes progressive breathlessness that, left unmanaged, becomes debilitating. Simple drainage provides temporary relief but fluid almost always returns, so a more definitive strategy is usually needed.27European Respiratory Review. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
The two main options are chemical pleurodesis and indwelling pleural catheters. Pleurodesis uses a chemical irritant, most often sterile medical-grade talc, instilled into the pleural space to create inflammation and adhesion between the two pleural surfaces, preventing fluid from re-accumulating. It works in about 60% to 80% of patients, provided the underlying lung is not trapped by tumor. The alternative, an indwelling catheter, allows regular home drainage and works even when the lung is trapped. Both approaches are comparably effective at relieving breathlessness, and the choice often comes down to patient preference and local availability of thoracoscopy.28European Respiratory Review. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment However, as noted earlier, pleurodesis after biopsy has been associated with an increased risk of chest wall metastasis at biopsy sites, so the timing and sequence of interventions matter.29PubMed Central. Incidence and Risk Factors of Chest Wall Metastasis at Biopsy Sites in Patients with Malignant Pleural Mesothelioma
The Role of Hypoxia and Blood Vessel Growth
The tumor microenvironment in mesothelioma tends to be low in oxygen, and that hypoxia acts as a promoter of further spread. Low-oxygen conditions trigger changes in gene activity that reduce normal cell death, boost signaling pathways that drive growth, and encourage invasion and metastasis. Hypoxia also feeds a vicious cycle: it upregulates VEGF and other molecules that stimulate the growth of abnormal blood vessels, which in turn are leaky and poorly organized, perpetuating the hypoxic conditions.30PubMed Central. Antiangiogenic Strategies in Mesothelioma This has made antiangiogenic therapy, meaning drugs that block new blood vessel formation, an area of active investigation. While no antiangiogenic agent has yet become a standard part of mesothelioma treatment, several have been tested in clinical trials, and bevacizumab added to chemotherapy has shown benefit in some settings. The challenge is that blocking blood vessel growth can also impair drug delivery to the tumor, creating a therapeutic paradox that researchers are still working to resolve.